NEWS Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results Baltimore, MD

Champions Biotechnology Reports

Fiscal 2010 First Quarter Financial Results

Baltimore, MD September 14,

2009-Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a

company engaged in the development of advanced preclinical platforms and tumor

specific data to enhance the value of oncology drugs, today announced its

financial results for the first quarter ended July 31, 2009. Full details

of the Company's financial results are available in the Company's

Form 10-Q at www.championsbiotechnology.com.

Total revenues for the first quarter

of 2010 were $962,000 as compared to $673,000 in the first quarter of 2009, an

increase of 43%. This increase was derived from the Company's

Personalized Oncology business, which generated revenues of $899,000 for the

first quarter of 2010 compared to $616,000 in the comparable quarter of last

year. This increase consisted of increases in Personalized Oncology Tumorgraft

studies and vaccines, partially offset by a decrease in revenues from physician

panels. Preclinical eValuation revenues for three months ended July 31,

2009, and 2008 were $63,000 and $57,000, respectively.

Costs of Personalized Oncology

services for the first quarter of 2010 was $634,000 as compared to $226,000 in

the first quarter of 2009, an increase of 181%. The cost of Personalized

Oncology services increased due to an increase in the number of Tumorgraft

studies, which have higher expenses (lower gross margins) than revenues derived

from our physician panels. In addition, the Company recognized the costs of a

vaccine development study which required additional up front expenses. Cost of

Preclinical eValuation services for the three months ended July 31, 2009,

and 2008 were $34,000 and $34,000, respectively.

Research and Development expenses

for the first quarter of 2010 was $496,000 as compared to $231,000 in the

comparable quarter of 2009, an increase of 115%. The increase in research and

development resulted from the Company's continued efforts to build its

Tumorgraft platform and development costs associated with securing the

Company's future drug pipeline candidates.

Administrative expenses for the first quarter of 2010 was $806,000 as compared

to $334,000 in the comparable quarter of 2009, an increase of 141%. The

increase is primarily due to the continued investment in our corporate

infrastructure to support our overall growth and expansion into Israel and the

For the first quarter ended

July 31, 2009, the Company reported a net loss of $1,003,000 or ($0.03)

per share compared to a net loss of $131,000 or $0.00 per share in the

comparable quarter in 2009.

The Company's cash and cash equivalents

on July 31, 2009 was $1,530,000 compared to $2,745,000 at April 30,

Doug Burkett, Ph.D., President of

Champions Biotechnology, Inc., commented, "this past quarter we saw

continued improvement in the Company's revenue growth and we continued to

build our Tumorgraft platform." In addition, the Company continued to

make progress during the quarter on the following fronts:

Furthermore, as previously

announced, since the end of the July 31, 2009 quarter, the Company entered

into a major collaboration agreement with PinnacleCare, the world's

leading private health advisory. This partnership will enable Champions to

educate many more physicians regarding the Company's services and assist

many more individuals with cutting edge research to personalize their cancer

For more information regarding

Champions Biotechnology's business and recent news, please visit

www.championsbiotechnology.com. To learn more about personalized cancer

treatment, please visit www.personalizedcancertreatment.com.

About Champions Biotechnology,

Champions Biotechnology, Inc. is engaged in the development of

advanced preclinical platforms and tumor specific data to enhance and

accelerate the value of oncology drugs. The Company's Preclinical

Platform is a novel approach based upon the implantation of primary human

tumors in immune deficient mice followed by propagation of the resulting

engraftments (Biomerk Tumorgrafts ) in a manner that preserves the

biological characteristics of the original human tumor. Early studies suggest

that unlike traditional xenografts, these Tumorgrafts closely reflect human

cancer biology and their response to drugs is predictive of clinical outcomes

in cancer patients. Champions Biotechnology leverages its preclinical platform

to evaluate drug candidates and to develop a portfolio of novel therapeutic

candidates. As drugs progress through early stage development, the Company

plans to sell, partner or license them to pharmaceutical and/or biotechnology

companies, as appropriate. The Company also offers its predictive preclinical

platform and tumor specific data to physicians for personalized patient care

and to companies for evaluation of oncology drugs in models that integrate

prognostic testing with biomarker discovery.

This press release contains

"forward-looking statements" (within the meaning of the Private

Securities Litigation Act of 1995) that inherently involve risk and

uncertainties. Champions Biotechnology generally uses words such as

"believe," "may," "could,"

"will," "intend," "expect,"

"anticipate," "plan," and similar expressions to

identify forward-looking statements. One should not place undue reliance on

these forward-looking statements. The Company's actual results could

differ materially from those anticipated in the forward-looking statements for

many unforeseen factors. See Champions Biotechnology's Form

10-K for the fiscal year ended April 30, 2009 for a discussion of

such risks, uncertainties and other factors. Although the Company believes the

expectations reflected in the forward-looking statements are reasonable, they

relate only to events as of the date on which the statements are made, and

Champions Biotechnology's future results, levels of activity, performance

or achievements may not meet these expectations. The Company does not intend to

update any of the forward-looking statements after the date of this press

release to conform these statements to actual results or to changes in

Champions Biotechnology's expectations, except as required by law.

For more news and information on

Champions Biotechnology, Inc., please visit www.IRGnews.com/coi/CSBR where you